Your browser is no longer supported. Please, upgrade your browser.
AUPH Aurinia Pharmaceuticals Inc. daily Stock Chart
Aurinia Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.37 Insider Own17.11% Shs Outstand126.25M Perf Week5.46%
Market Cap2.00B Forward P/E- EPS next Y-0.55 Insider Trans0.00% Shs Float110.24M Perf Month8.79%
Income- PEG- EPS next Q-0.14 Inst Own49.68% Short Float3.80% Perf Quarter18.92%
Sales0.32M P/S6288.78 EPS this Y-53.00% Inst Trans- Short Ratio4.09 Perf Half Y-8.12%
Book/sh2.12 P/B7.47 EPS next Y45.50% ROA- Target Price11.50 Perf Year224.59%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range4.65 - 21.93 Perf YTD-21.82%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-27.77% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low240.65% ATR0.56
Employees62 Current Ratio- Sales Q/Q0.00% Oper. Margin- RSI (14)58.44 Volatility4.14% 3.51%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.86 Prev Close16.05
ShortableYes LT Debt/Eq- EarningsAug 11 AMC Payout- Avg Volume1.02M Price15.84
Recom1.70 SMA203.36% SMA507.21% SMA2000.39% Volume879,220 Change-1.31%
Jun-17-20Initiated BTIG Research Buy $20
May-05-20Initiated Cowen Outperform
Jan-10-20Initiated Jefferies Buy $27
Dec-16-19Reiterated H.C. Wainwright Buy $25 → $32
Mar-16-18Reiterated Cantor Fitzgerald Overweight $14 → $16
Feb-08-18Initiated RBC Capital Mkts Outperform $9
Oct-30-17Reiterated H.C. Wainwright Buy $10 → $12
May-18-17Reiterated H.C. Wainwright Buy $12 → $10
Apr-11-17Initiated Cantor Fitzgerald Overweight $14
Mar-22-17Reiterated FBR & Co. Outperform $9 → $11
Dec-30-16Reiterated H.C. Wainwright Buy $10 → $8
Aug-17-16Reiterated H.C. Wainwright Buy $7 → $10
Jun-30-16Initiated H.C. Wainwright Buy $7
May-08-15Initiated MLV & Co Buy $9
Oct-28-20 07:41AM  
Oct-27-20 04:05PM  
Oct-22-20 04:15PM  
Oct-16-20 06:28AM  
Oct-14-20 06:05AM  
Oct-05-20 01:30PM  
Oct-02-20 05:00PM  
Sep-29-20 06:44PM  
Sep-28-20 06:05AM  
Sep-16-20 03:26PM  
Sep-10-20 06:05AM  
Sep-04-20 06:04PM  
Aug-11-20 05:29PM  
Aug-04-20 12:30PM  
Jul-30-20 06:05AM  
Jul-28-20 12:33PM  
Jul-27-20 10:15AM  
Jul-23-20 06:59PM  
Jul-22-20 11:05PM  
Jul-21-20 05:27PM  
Jul-18-20 10:02AM  
Jul-15-20 01:15PM  
Jul-12-20 08:15PM  
Jun-22-20 06:05AM  
Jun-09-20 10:20AM  
Jun-08-20 03:00AM  
Jun-05-20 07:05AM  
Jun-04-20 06:34AM  
Jun-03-20 06:05AM  
Jun-01-20 04:05PM  
May-26-20 08:16AM  
May-20-20 10:04AM  
May-19-20 04:26PM  
May-15-20 04:05PM  
May-14-20 05:35PM  
May-07-20 06:05AM  
May-05-20 12:30PM  
Apr-29-20 01:12PM  
Apr-27-20 06:05AM  
Apr-21-20 07:33AM  
Apr-20-20 06:05AM  
Apr-08-20 07:32PM  
Mar-18-20 06:05AM  
Mar-17-20 06:00AM  
Mar-16-20 06:05AM  
Mar-12-20 07:00AM  
Mar-05-20 04:02PM  
Mar-04-20 08:36AM  
Mar-03-20 06:30AM  
Feb-25-20 06:30AM  
Feb-21-20 04:05PM  
Feb-04-20 10:20AM  
Jan-23-20 09:11AM  
Jan-21-20 05:01AM  
Jan-02-20 07:00AM  
Dec-13-19 10:29AM  
Dec-12-19 09:26AM  
Dec-10-19 04:16PM  
Dec-09-19 09:00PM  
Dec-07-19 08:35AM  
Dec-06-19 07:39AM  
Dec-05-19 10:08AM  
Dec-04-19 04:59PM  
Dec-03-19 06:30AM  
Dec-02-19 08:38AM  
Nov-14-19 05:15PM  
Nov-13-19 04:05PM  
Nov-09-19 03:55PM  
Nov-07-19 10:30AM  
Nov-06-19 04:05PM  
Oct-31-19 06:30AM  
Oct-17-19 10:11AM  
Oct-16-19 06:30AM  
Oct-15-19 06:15AM  
Oct-07-19 08:34AM  
Sep-26-19 04:05PM  
Sep-23-19 08:52AM  
Sep-19-19 11:01AM  
Sep-13-19 05:11PM  
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.